

12-1-2017

Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): epidemiologic correlates for 2016 surveillance isolates

Erik Munson

Marquette University, erik.munson@marquette.edu

Heather Zeman

Marquette University

Erin Hueppchen

Marquette University

Authors:

Erik Munson, PhD, D(ABMM),
College of Health Sciences
Marquette University
Milwaukee, Wisconsin; and
Wisconsin Clinical Laboratory Network
Technical Advisory Group (LabTAG)
Madison, Wisconsin

Heather Zeman
Erin Hueppchen
College of Health Sciences
Marquette University
Milwaukee, Wisconsin

Corresponding author:

Erik Munson, PhD
Department of Clinical Laboratory
Science
Marquette University
P.O. Box 1881
Milwaukee, WI 53201-1881
Telephone: (414) 288-5848
Facsimile: (414) 288-7948
Email: erik.munson@marquette.edu

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): epidemiologic correlates for 2016 surveillance isolates

ABSTRACT

Background: The Centers for Disease Control and Prevention advocate data collection and monitoring as one facet of a comprehensive approach to combat antimicrobial resistance in the United States. However, a paucity of such data exists at the local/state level for common disease-causing organisms.

Methods: To begin to characterize epidemiologic correlates of antibacterial resistance in Wisconsin, data analyses were performed with respect to isolates in the Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) 2016 collection. In addition to submitting isolates of *Escherichia coli*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, and *Streptococcus pneumoniae*, participating laboratories were also requested to submit data regarding patient age, specimen source, and location of patient service.

Results: Fifty-five percent of isolates were of outpatient origin (including emergency department). In general, isolates derived from inpatients were more likely to demonstrate higher resistance rates than those from outpatient locations. Upon further stratification, isolates from emergency department encounters generally exhibited higher susceptibility rates than those from outpatient clinics. Sixty-seven percent of isolates emanated from skin and soft tissue or invasive sites. Delineation of specimen source played a minimal role in prediction of antimicrobial resistance. Older patients were more likely to generate isolates of *E coli* and *P mirabilis* exhibiting resistance to agents such as fluoroquinolones and trimethoprim-sulfamethoxazole.

Conclusions: SWOTARE facilitates epidemiologic investigations into resistance at the local/state level. Investigations are warranted to further delineate differences in isolates derived from emergency department and outpatient clinic visits. Characterizations at the demographic level could impact local empiric treatment guidelines and antimicrobial stewardship throughout Wisconsin.

The Centers for Disease Control and Prevention (CDC) have recently identified 17 groupings of bacterial and fungal organisms collectively responsible for at least two million annual illnesses and 23 000 deaths on the basis of antimicrobial resistance.¹ CDC has additionally advocated a 4 faceted approach to address the paradigm of national antimicrobial resistance, 1 of which involves timely surveillance for the emergence of novel and unique patterns of resistance. The value of such surveillance efforts has been championed by pioneers in the field.²

We have described implementation of the Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) program.³ In summary, a centralized microbiology laboratory assesses representative bacterial isolates using a standardized antimicrobial susceptibility testing method. These isolates are submitted by 22 clinical laboratories with widespread distribution throughout Wisconsin. With such infrastructure, we currently have capability of monitoring 3 of the CDC-targeted organism groups.¹ Two of these, multidrug-resistant *Pseudomonas aeruginosa* and drug-resistant *Streptococcus pneumoniae*, are responsible for 51 000 healthcare-associated

infections⁴ and 4 million general infections,⁵ respectively, on an annual basis. These infections further translate into resistance rates approximating 13% to 30%,^{5,6} with annual deaths attributable to resistant strains estimated at 440 (*P aeruginosa*)⁷ and 7000 (*S pneumoniae*).⁵ Furthermore, collected *Escherichia coli* can be monitored for evidence of carbapenemase and extended-spectrum β -lactamase (ESBL) production. It is estimated that these resistance mechanisms are responsible for greater than 10 000 healthcare-associated infections in the United States annually, with approximately 700 attributable deaths.^{4,6-8}

An additional component of the SWOTARE program involves submission of isolate-specific epidemiologic data from participating clinical laboratories. Such data may not be readily available in the course of surveillance endeavors strictly involving analysis of antibiogram data.⁹ Moreover, as part of the CDC-advocated surveillance approach,¹ it is recommended that data be collected with respect to risk factors for antimicrobial resistance. This report provides introductory information relative to the epidemiology of antimicrobial resistance in Wisconsin, as generated by the 2016 SWOTARE collection.

METHODS

SWOTARE Program

Establishment of the SWOTARE surveillance network, along with isolate submission and susceptibility testing protocols/interpretation,¹⁰ has been described.³ In summary, clinical microbiology laboratories in Ashland, Spooner, St. Croix Falls, and Eau Claire (northwest region); Marshfield, Weston, and Stevens Point (northcentral region); Manitowoc, Sturgeon Bay, and Green Bay (northeast region); Platteville, Prairie du Chien, Viroqua, and La Crosse (southwest region); Fort Atkinson, Janesville, and Madison (southcentral region); Fond du Lac, Neenah, and Appleton (Lake Winnebago region); and, West Bend and Milwaukee (southeast region) participated in the program.

Isolates and Demographic Data

Study sites were requested to collect consecutive isolates of *E. coli*, *Proteus mirabilis*, *P. aeruginosa*, and *S. pneumoniae* identified from in-house culture of clinically significant infection. Laboratories were further requested to supply limited patient demographic information, including age, sex, anatomic source, patient service location, and whether the healthcare encounter involved an intensive care unit stay. Access to protected health information for the purpose of the investigation was granted by the Marquette University Institutional Review Board. Because of the lack of direct involvement in the collection of specimens and because of the utilization of de-identified isolates from routine clinical care, the Review Board did not consider the SWOTARE program to be actively engaged in human subjects research.

Data Analysis

Genus-specific percentage susceptible, intermediate (susceptible-dose dependent for cefepime and *Enterobacteriaceae* combinations¹¹), and resistant values, as well as minimum inhibitory concentration (MIC) determinations (MIC₅₀ and MIC₉₀) were generated. Such analyses were applied to statewide isolates as a whole, in addition to characterizations on the basis of patient healthcare encounter location, specimen source, and patient age. Only patient service location, specimen source, and age delineations with n ≥ 25 were utilized for comparisons. The significance test of proportions determined if differences in susceptibility percentage were significant. The α level was set at .05 before the investigations commenced, and all P values are 2-tailed.

RESULTS AND EPIDEMIOLOGIC DISCUSSION

Patient Demographics and Isolate Distribution by Patient Location

One thousand eighty isolates were submitted to the program and tested in 2016. Of this total, complete demographic data were provided for 1055 (97.7%) isolates. Five hundred sixty-one (53.2%) isolates were derived from women. Mean patient age was 62.5 years, with a median of 66. Six general patient service categories (Figure 1) accounted for 94.8% of all patient isolates. As a result of the inclusion of data from long-term care facilities as inpatient data, the percentage composition of inpatient isolates was 45.4%, the largest component of which was internal medicine (25.6% of all isolates). Outpatient data consisted of outpatient clinic–derived isolates (30.0% of all isolates) and those collected from emergency departments (24.6% of all isolates).




Figure 1. Distribution of isolates assessed by the 2016 SWOTARE program, delineated by healthcare location of specimen collection.




Figure 2. Distribution of isolates assessed by the 2016 SWOTARE program, delineated by specimen source.

Isolate Distribution by Specimen Source

Greater than two-thirds of specimens submitted to the SWOTARE program in 2016 were of skin and soft tissue or invasive origin (Figure 2). Invasive isolates included those derived from blood (354 isolates), cerebrospinal fluid (4), paracentesis fluid (1), hardware (1), bone (1) and bile (1). Sixteen percent of isolates were derived from urogenital (172 urine, 1 Bartholin cyst) sources. Distribution of lower respiratory tract isolates (12.6% of all isolates) included sputum (111), bronchoalveolar lavage (8), endotracheal aspiration (7), bronchial washings (6), thoracentesis fluid (3), and pleural fluid (1). Upper respiratory tract isolates included those derived from ear (18 isolates), nose (9), throat (8), eye (7), and sinus (4) specimens.

Profile by Patient Location

We compared differences in susceptibility rates for antimicrobial/organism combinations as a function of patient care location from which the isolate was derived. Table 1A demonstrates one example of inpatient isolates exhibiting an increased antimicrobial

SURVEILLANCE OF WISCONSIN ORGANISMS FOR TRENDS IN ANTIMICROBIAL RESISTANCE AND EPIDEMIOLOGY

Table 1. MIC₅₀ and MIC₉₀ Distributions and Categorical Interpretations of *Proteus mirabilis* Isolate Susceptibility to Levofloxacin by A: Inpatient and Outpatient and B: Most Prevalent Patient Locations, Wisconsin 2016

A						
Location	n	MIC ₅₀	MIC ₉₀	CLSI Breakpoints 2/4/8		
				Susceptible	Intermediate	Resistant
Outpatient	155	≤0.25	4	89.0	1.9	9.1
Inpatient	116	≤0.25	>32	69.0	3.4	27.6
Wisconsin		≤0.25	16	81.0	2.5	16.5

B						
Location	n	MIC ₅₀	MIC ₉₀	CLSI Breakpoints 2/4/8		
				Susceptible	Intermediate	Resistant
Clinics	109	≤0.25	16	86.2	1.8	11.9
Internal Medicine	64	≤0.25	>32	67.2	4.7	28.1
Emergency Department	46	≤0.25	1	95.6	2.2	2.2
Intensive Care Unit	10	0.5	8	70.0	10.0	20.0
Long-term Care	23	2	>32	65.2	0.0	34.8
Surgery	13	≤0.25	32	92.3	0.0	7.7
Wisconsin		≤0.25	16	81.0	2.5	16.5

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

resistance profile over that of outpatient isolates. This inpatient *P. mirabilis* profile is characterized by a decreased levofloxacin percentage susceptible value, as well as an elevated MIC₉₀ value. Further subcategorization of this antimicrobial/organism paradigm is represented in Table 1B. The frank resistance rates and increased MIC₉₀ values within this profile, as well as a majority of other antimicrobial/organism profiles (data not illustrated), justify inclusion of long-term care facilities with inpatient data. Initial insight into differences in susceptibility between isolates derived from emergency department visits (95.6% susceptibility) and those from internal medicine and outpatient clinic encounters (67.2% and 86.2%, respectively) was also observed.

On the basis of achieved *n* values, subsequent analysis was restricted to internal medicine, emergency department, and outpatient clinics. Greater than 61% of individual *E. coli*, *P. mirabilis*, *P. aeruginosa*, and *S. pneumoniae*/antimicrobial combinations revealed susceptibility rates that differed by less than 10% between the 3 healthcare locations (data not illustrated). Noteworthy exceptions included a cefazolin susceptibility difference of 16.1% between emergency department and internal medicine *E. coli* isolates and a penicillin susceptibility difference of 22.1% between emergency department and internal medicine *S. pneumoniae* isolates.

The potential influence of patient service location on empiric regimen choice is demonstrated in Table 2. For each of the 4 organisms investigated in the surveillance program, a higher proportion of antimicrobials demonstrated greater *in vitro* potency on emergency department–derived isolates when

Table 2. Frequency of Antimicrobial/Organism Testing Combinations Yielding Highest Percentage-Susceptible Values Compared by Location of Patient Encounter, Wisconsin 2016^a

Organism	Patient Encounter Location		
	Outpatient Clinic	Internal Medicine	Emergency Department
<i>Escherichia coli</i>	18.8	31.3	50.0
<i>Proteus mirabilis</i>	42.9	0.0	92.9
<i>Pseudomonas aeruginosa</i>	44.4	11.1	55.6
<i>Streptococcus pneumoniae</i>	0.0	7.7	92.3

^a Cumulative values may not equal 100% due to rounding or to multiple patient locations sharing highest percentage-susceptible value.

compared with outpatient clinic- and internal medicine–derived isolates. This dichotomy was especially noted with *S. pneumoniae*, as 92.3% of antimicrobial/emergency department–derived isolate combinations demonstrated most *in vitro* potency when compared with internal medicine- and outpatient clinic–derived isolates (7.7% and 0%, respectively).

Studies attempting to associate increased antimicrobial resistance with patient service location have often been performed in the context of urinary tract infection. In general, healthcare-

associated urinary tract pathogens possess increased resistance rates when compared with community-acquired agents of urinary tract infection (particularly with respect to *E coli* resistance to fluoroquinolone agents). Examples of such data emanate from large study collections in international centers that are derived from antibiogram data^{12,13} or from surveillance programs.¹⁴ From a 4-year Swiss antibiogram study, Lamothe et al¹⁵ reported that community-acquired strains of *E coli* and *P aeruginosa* (irrespective of specimen source) demonstrated higher susceptibility rates when compared to hospital-acquired strains. With respect to *P aeruginosa*, this group further implied that differences in ciprofloxacin and ceftazidime susceptibility were a function of specific inpatient unit.

Additional investigations have focused on emergency department populations. Zatorski et al¹⁶ compared *E coli* antibiograms from non-intensive care unit inpatient urine cultures with those derived from emergency department patients and found increased ceftriaxone and ciprofloxacin susceptibility rates in the latter demographic. Draper et al¹⁷ used an antibiogram approach to determine that emergency department-derived *E coli* isolates (regardless of specimen source) demonstrated increased susceptibility rates to ampicillin, levofloxacin, and trimethoprim-sulfamethoxazole when compared with hospital-wide isolates. A similar paradigm was observed with *P aeruginosa* and aztreonam.

Profile by Specimen Source

Differences in susceptibility rates were also compared on basis of specimen source. With respect to each organism, source-specific n values allowed comparisons among 3 specimen sources. Greater

Table 3. Frequency of Percentage Susceptibility Value Differences for Combinations of Organisms and Antimicrobial Agents Compared by Top 3 Specimen Sources, Wisconsin 2016 ^a

Organism	Maximum Percentage-Susceptible Difference			
	<5%	5-10%	10-20%	>20%
<i>Escherichia coli</i> ^b	38.9	61.1	0.0	0.0
<i>Proteus mirabilis</i> ^c	72.2	16.7	5.6	5.6
<i>Pseudomonas aeruginosa</i> ^d	55.6	22.2	22.2	0.0
<i>Streptococcus pneumoniae</i> ^e	33.3	53.3	13.3	0.0

^a Individual specimen source (skin and soft tissue, invasive, urogenital, lower respiratory, upper respiratory) required 25 isolates to qualify for this analysis.

^b Top 3 specimen sources were invasive, skin and soft tissue, and urogenital.

^c Top 3 specimen sources were skin and soft tissue, urogenital, and invasive.

^d Top 3 specimen sources were skin and soft tissue, invasive, and lower respiratory.

^e Top 3 specimen sources were invasive, lower respiratory, and upper respiratory.

Table 4. MIC₅₀ and MIC₉₀ Distributions and Categorical Interpretations of *Escherichia coli* Isolate Susceptibility to A: Levofloxacin, and B: Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016

A						
				CLSI Breakpoints 2/4/8		
Age, y	n	MIC ₅₀	MIC ₉₀	Susceptible	Intermediate	Resistant
20-39	40	≤0.25	0.5	92.5	0.0	7.5
40-59	68	≤0.25	16	80.9	0.0	19.1
60-79	159	≤0.25	32	74.8	0.0	25.2
≥80	90	≤0.25	16	78.9	0.0	21.1
Wisconsin		≤0.25	16	79.9	0.0	20.1

P = .02 for susceptibility rate of 20-39 years versus 60-79 years.

P = .06 for susceptibility rate of 20-39 years versus ≥80 years.

B						
				CLSI Breakpoints 2/4		
Age, y	n	MIC ₅₀	MIC ₉₀	Susceptible	Intermediate	Resistant
20-39	40	≤1	>16	82.5		17.5
40-59	68	≤1	>16	85.3		14.7
60-79	159	≤1	>16	80.5		19.5
≥80	90	≤1	>16	77.8		22.2
Wisconsin		≤1	>16	80.7		19.3

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

Table 5. MIC₅₀ and MIC₉₀ Distributions and Categorical Interpretations of *Proteus mirabilis* Isolate Susceptibility to A: Ciprofloxacin, and B: Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016

A						
				CLSI Breakpoints 1/2/4		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	25	≤0.25	1	92.0	0.0	8.0
40-59	60	≤0.25	16	80.0	1.7	18.3
60-79	110	≤0.25	32	72.7	3.6	23.6
≥80	71	≤0.25	32	67.6	8.5	23.9
Wisconsin		≤0.25	32	75.6	4.3	20.1

P = .04 for susceptibility rate of 20-39 years versus 60-79 years.

P = .02 for susceptibility rate of 20-39 years versus ≥80 years.

B						
				CLSI Breakpoints 2/4		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	25	≤1	≤1	100		0.0
40-59	60	≤1	>16	85.0		15.0
60-79	110	≤1	>16	77.3		22.7
≥80	71	≤1	>16	80.3		19.7
Wisconsin		≤1	>16	82.4		17.6

P = .04 for susceptibility rate of 20-39 years versus 40-59 years.

P = .008 for susceptibility rate of 20-39 years versus 60-79 years.

P = .02 for susceptibility rate of 20-39 years versus ≥80 years.

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

than 86% of individual *E coli*, *P mirabilis*, and *S pneumoniael* antimicrobial combinations exhibited susceptibility rates that varied by <10% between specimen source (Table 3). In contrast, 22.2% of *P aeruginosa*/antimicrobial combinations involved susceptibility variation of >10% between specimen sources. This was characterized by increased meropenem and aztreonam susceptibility rates for invasive *P aeruginosa* isolates (data not illustrated).

In essence, influence of specimen source on potential empiric regimen choice was less pronounced than that described for location of patient encounter. As one example, urogenital isolates predicted a marginally greater proportion of highly susceptible antimicrobial agents for *P mirabilis* (50.0%) when compared with skin and soft-tissue isolates (35.7%; data not illustrated). Although participating laboratories were asked to focus collection efforts on isolates derived from skin and soft tissue, invasive, and lower respiratory tract sources, lower-volume laboratories on occasion submitted urinary tract isolates to the SWOTARE program to fulfill an organism quota. The aforementioned analyses (ie, marginal susceptibility differences among specimen sources) suggest that inclusion of this additional specimen source had minimal impact on regional susceptibility rates and contributed to overall representative sampling within the geographic area.

Profile by Patient Age

Finally, age-related determinants of antimicrobial resistance for each of the 4 surveillance organisms were investigated by focusing on the 2 to 3 antimicrobial agents with the lowest percentage-susceptible values, as elucidated in a previous report.³ *E coli* isolates derived from 20- to 39-year-olds demonstrated more susceptibility to levofloxacin than those from 60- to 79-year-olds (*P* = .02; Table 4A). These isolates also trended toward greater susceptibility when compared with those from patients aged ≥ 80 years (*P* = .06). No age-related relationships were noted with trimethoprim-sulfamethoxazole (Table 4B) and ampicillin susceptibility.

With respect to *P mirabilis*, isolates derived from patients aged 20 to 39 years yielded increased rates of ciprofloxacin susceptibility when compared with isolates from patients aged 60 to 79 years and ≥ 80 years (*P* = .04 and *P* = .02, respectively; Table 5A). Similarly, *P mirabilis* isolates from 20- to 39-year-old patients exhibited increased trimethoprim-sulfamethoxazole susceptibility when compared with all other age groups (*P* ≤ .04; Table 5B). No significant differences were noted when ampicillin susceptibility was stratified by patient age.

P aeruginosa isolates from 40- to 59-year-old patients exhibited decreased ciprofloxacin susceptibility when compared with patients over the age of 60 years (*P* ≤ .03; Table 6A). Similarly, *P aeruginosa*

Table 6. MIC₅₀ and MIC₉₀ Distributions and Categorical Interpretations of *Pseudomonas aeruginosa* Isolate Susceptibility to A: Ciprofloxacin, and B: Aztreonam by Age, Wisconsin 2016

A						
				CLSI Breakpoints 1/2/4		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	17	≤0.25	0.5	94.1	0.0	5.9
40-59	48	≤0.25	8	77.1	8.3	14.6
60-79	86	≤0.25	2	90.7	2.3	7.0
≥80	48	≤0.25	1	93.8	0.0	6.3
Wisconsin		≤0.25	2	88.2	3.3	8.5

P = .03 for susceptibility rate of 40-59 years versus 60-79 years.

P = .02 for susceptibility rate of 40-59 years versus ≥80 years.

B						
				CLSI Breakpoints 8/16/32		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	17	8	8	94.1	5.9	0.0
40-59	48	4	32	77.1	10.4	12.5
60-79	86	8	16	75.6	17.4	7.0
≥80	48	4	16	89.6	6.3	4.2
Wisconsin		8	16	81.0	12.3	6.6

P = .05 for susceptibility rate of 60-79 years versus ≥80 years.

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

isolates derived from patients aged 60 to 79 years demonstrated less susceptibility to aztreonam than isolates from patients aged ≥ 80 years (*P* = .05; Table 6B). No significant age delineations were determined with respect to *S pneumoniae* susceptibility to either penicillin (*P* ≥ .22; Table 7A) or erythromycin (*P* ≥ .18; Table 7B).

Swami and Banerjee¹⁸ used an antibiogram approach to stratify antimicrobial resistance patterns in *E coli* and *S pneumoniae* by patient age (< 18 years; 18-64 years; ≥ 65 years) at a United States institution. The authors noted that their institution-wide antibiogram underestimated resistance profiling in older patients (particularly with respect to ciprofloxacin and *E coli*) when compared with a specialized antibiogram devised for populations aged ≥ 65 years. In a European study, Grignon et al¹⁹ reported a risk factor for increased ciprofloxacin resistance in emergency department *E coli* isolates as being age ≥ 45 years. Data presented in tables 4 through 7 used an isolate-based approach (stratified over an increased number of age groupings) to corroborate these findings. In addition, we were able to extend this paradigm to an additional member of *Enterobacteriaceae* (Table 5) with another antimicrobial class (trimethoprim-sulfamethoxazole; Table 5B). Swami and Banerjee¹⁸ also reported decreased *S pneumoniae* susceptibility to a number of antimicrobial classes in pediatric populations. We were unable to analyze SWOTARE data for a comparative phenomenon at this time due to low n values for patients under the age of 20 years. Other *S pneumoniae* comparisons throughout this study were limited to an extent by disproportionate isolate contributions across a number of geographic regions.³ Increased isolate quota

in future surveillance collections will improve the validity of antimicrobial-resistant *S pneumoniae* epidemiologic findings.

In addition to the demographic factors affecting antimicrobial resistance that are described in this report, one cannot discount the contribution of geographic location. In the context of the 2016 SWOTARE collection, several geographic paradigms were noted.³ Grignon et al¹⁹ investigated *E coli* antimicrobial resistance in the emergency department setting in a region of France (with population of 3.6 million) with an area equivalent to the state of Maryland. Of 10 participating emergency departments, 5 were specifically cited as significant risk factors for increased fluoroquinolone resistance in uropathogenic *E coli*.

In discussing the current status of antimicrobial resistance in the United States, the CDC cited gaps in general knowledge that involved limited national and state capacity for the detection of emerging antimicrobial resistance trends.¹ Past state-based efforts,^{20,21} as well as those described within the context of the SWOTARE program, are therefore necessary to supplement data generated by national programs. Moreover, the SWOTARE program already possesses the infrastructure to allow for both annual assessment of resistance trending and a broadening of scope via introduction of additional organism groups into the surveillance paradigm. Boucher et al²² listed a number of pathogens (vancomycin-resistant *Enterococcus faecium*, methicillin-resistant *Staphylococcus aureus*, ESBL-producing *Klebsiella* spp. and *E coli*, carbapenemase-producing *Klebsiella* spp., *Acinetobacter baumannii*, *P aeruginosa*, and *Enterobacter* spp.) for which antimicrobial agent

SURVEILLANCE OF WISCONSIN ORGANISMS FOR TRENDS IN ANTIMICROBIAL RESISTANCE AND EPIDEMIOLOGY

Table 7. MIC₅₀ and MIC₉₀ Distributions and Categorical Interpretations of *Streptococcus pneumoniae* Isolate Susceptibility to A: Penicillin, and B: Erythromycin by Age, Wisconsin 2016

A						
				CLSI Breakpoints 0.06/0.12*		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	23	≤0.015	0.25	60.9		39.1
40-59	37	≤0.015	2	75.7		24.3
60-79	72	≤0.015	0.5	72.2		27.8
≥80	44	≤0.015	1	68.2		31.8
Wisconsin		≤0.015	1	70.3		29.7

B						
				CLSI Breakpoints 0.25/0.5/1		
Age, y	n	MIC₅₀	MIC₉₀	Susceptible	Intermediate	Resistant
20-39	23	≤0.06	>4	52.2	0.0	47.8
40-59	37	≤0.06	>4	62.2	0.0	37.8
60-79	72	2	>4	48.6	0.0	51.4
≥80	44	≤0.06	>4	52.3	0.0	47.7
Wisconsin		≤0.06	>4	54.2	0.0	45.8

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

*Breakpoints for meningeal *S pneumoniae* isolates.

research and development efforts have become increasingly necessary. Before such advancements are made, close surveillance of currently available agents is essential. The SWOTARE program currently allows for statewide monitoring of 3 of the 7 aforementioned ESKAPE pathogens in Wisconsin, as well as 1 additional pathogen cited by the World Health Organization as another focus for development of alternative antimicrobial strategies.²³

CONCLUSIONS

A number of approaches have been considered in the monitoring of antimicrobial resistance patterns. One advantage of a surveillance paradigm based on isolate collection, such as the SWOTARE program, is its capability of ascribing demographic information to isolates. Testing within the SWOTARE program in 2016 revealed resistance variation with respect to a number of antimicrobial/organism combinations. These differences were more relative to location of patient encounter and patient age when compared with specimen source. Year 1 of this surveillance project also revealed particular niches of potential emerging resistance that will be assessed in future seasons of isolate collection. All told, provision of these data to a broad audience may potentiate revision of local empiric therapy guidelines and contribute to antimicrobial stewardship efforts.

ACKNOWLEDGMENTS

Partial funding was granted by Marquette University College of Health Sciences. The authors are grateful to the following individuals for provision of isolates for the 2016 surveillance project and for additional coordinative assistance for this program:

Jorn Bansberg, Viroqua	Brooke Olson, Marshfield
Eric Beck, PhD, Milwaukee	Ray Podzorski, PhD, Madison
Tim Block, West Bend	Mattie Pitts, Spooner
Erin J. Bowles, Madison	Lynn Prellwitz, Manitowoc
Becky Brooks, Stevens Point	Tyler Radke, Green Bay
Kellie Diedrick, Green Bay	Karen Siebers, Neenah
Tracy Felland, Janesville	Brian Simmons, Prairie du Chien
Thomas Fritsche, MD, PhD, Marshfield	Mary A. Smith, St. Croix Falls
Ben Kaetterhenry, Appleton	Frances Spray-Larson, PhD, Fort Atkinson
Debra Kieler, Platteville	Janelle Stearns, Eau Claire
Joshua Kropp, Weston	Sarah Stoner, La Crosse
Kathy Lang, Ashland	Cara Tolliver, Sturgeon Bay
Kimber Munson, PhD, Waukesha	Ellen Wirtz, Fond du Lac
Maureen Napierala, Milwaukee	

REFERENCES

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf Accessed 27 April 2017.
2. Munson E. Biographical feature: Clyde Thornsberry, Ph.D. *J Clin Microbiol.* 2016;54(2):250-253.
3. Munson E, Hueppchen E, Zeman H. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): introduction to the program and summary of 2016 geographic variation. Manuscript submitted for publication.
4. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med.* 2014;370(13):1198-1208.
5. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. *Vaccine* 2011;29(18):3398-3412.
6. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol.* 2013;34(1):1-14.
7. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clin Infect Dis.* 2009;49(8):1175-1184.
8. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant *Enterobacteriaceae*. *MMWR Morbid Mortal Wkly Rep.* 2013;62(9):165-170.
9. Munson E, Block TK, Bowles EJ, et al. Surveillance of Wisconsin antibacterial susceptibility patterns. *WMJ.* 2016;115(1):29-36.
10. Clinical and Laboratory Standards Institute (CLSI). M100-S26: Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
11. Clinical and Laboratory Standards Institute (CLSI). M100-S24: Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
12. Cullen IM, Manecksha RP, McCullagh E, et al. The changing pattern of antimicrobial resistance within 42,033 *Escherichia coli* isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009. *BJU Int.* 2012;109(8):1198-1206.
13. Smithson A, Ramos J, Bastida MT, et al. Differential characteristics of healthcare-associated compared to community-acquired febrile urinary tract infections in males. *Eur J Clin Microbiol Infect Dis.* 2015;34(12):2395-2402.
14. Jean SS, Coombs G, Ling T, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region; results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. *Int J Antimicrob Agents.* 2016;47(4):328-334.
15. Lamoth F, Wenger A, Prod'homme G, et al. Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection. *Infection.* 2010;38(4):249-253.
16. Zatorski C, Jordan JA, Cosgrove SE, Zocchi M, May L. Comparison of antibiotic susceptibility of *Escherichia coli* in urinary isolates from an emergency department with other institutional susceptibility data. *Am J Health Syst Pharm.* 72(24):2176-2180.
17. Draper HM, Farland JB, Heidel RE, May LS, Suda KJ. Comparison of bacteria isolated from emergency department patients versus hospitalized patients. *Am J Health Syst Pharm.* 70(23):2124-2128.
18. Swami SK, Banerjee R. Comparison of hospital-wide and age and location-stratified antibiograms of *S. aureus*, *E. coli*, and *S. pneumoniae*: age- and location-stratified antibiograms. *SpringerPlus.* 2013;2:63.
19. Grignon, Montassier E, Corvec S, et al. *Escherichia coli* antibiotic resistance in emergency departments. Do local resistance rates matter? *Eur J Clin Microbiol Infect Dis.* 2015;34(3):571-577.
20. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. *J Clin Microbiol.* 2002;40(4):1298-1302.
21. Polgreen PM, Beekmann SE, Chen YY, et al. Epidemiology of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant *Enterococcus* in a rural state. *Infect Control Hosp Epidemiol.* 2006;27(3):252-256.
22. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48(1):1-12.
23. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. <http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/> Accessed 27 April 2017.